Sign in

    Matthew Larew • William Blair

    Matthew Larew's questions to Alpha Teknova Inc (TKNO) leadership

    Matthew Larew's questions to Alpha Teknova Inc (TKNO) leadership • Q1 2025

    Question

    Matthew Larew questioned the risk of Q1 revenue strength being due to a pull-forward of orders and asked how potential upside from the resilience of daily-use products factored into maintaining the full-year outlook. He also asked how Teknova's portfolio is positioned for shifts toward non-animal research models like organoids.

    Answer

    CFO Matt Lowell addressed the order patterns, stating that the company has not detected any significant pull-in activity for its strong-performing catalog business. President and CEO Stephen Gunstream added that while a shift away from animal models is speculative and not near-term, Teknova's portfolio supports non-animal models like organoids, which could present a potential tailwind for the company if such a shift occurs.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Alpha Teknova Inc (TKNO) leadership • Q4 2024

    Question

    Matthew Larew inquired about the recent softening in customer demand, asking if it was more pronounced in February and which customer segments were most affected. He also asked about the composition of the new clinical customer pipeline and whether any large, one-time orders from 2024 could impact 2025 comparisons.

    Answer

    President and CEO Stephen Gunstream confirmed the softening was a recent phenomenon in late January and February, primarily among smaller, capital-constrained biotechs, but reiterated confidence in 15% growth for the Biopharma segment. He noted most new customers are in preclinical or Phase I stages. Both Gunstream and CFO Matthew Lowell clarified that unlike in 2023, there were no significant one-off orders in 2024 that would distort year-over-year comparisons, with no single customer representing more than 4% of total revenue.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Alpha Teknova Inc (TKNO) leadership • Q3 2024

    Question

    Matthew Larew of William Blair requested more detail on the path to long-term gross margin targets, asking for help in quantifying the drag from fixed capacity and how revenue leverage will translate to margin expansion. He also asked how the current customer engagement and sales process compare to the period before the market downturn, seeking a proxy for the effectiveness of assets and capabilities put in place over the last few years.

    Answer

    CFO Matt Lowell reiterated that there is substantial leverage in the P&L due to the high fixed-cost structure and that additional revenue drops through at approximately 70% margin, which can be used to model future progression. President and CEO Stephen Gunstream addressed customer engagement, noting that while customers previously delayed orders, they are now starting to re-engage. He stated that the company's value proposition of providing smaller, custom, quick-turnaround batches remains validated and well-suited for the market's future needs.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Stevanato Group SpA (STVN) leadership

    Matthew Larew's questions to Stevanato Group SpA (STVN) leadership • Q1 2025

    Question

    Matthew Larew asked for clarification on the tariff impact within guidance, the current and future U.S. manufacturing capacity to meet domestic demand, and the full-year outlook for vial destocking and growth.

    Answer

    CFO Marco Dal Lago confirmed the guidance includes a net tariff impact of approximately €4.5 million to operating profit, after accounting for price transfers and supply chain effects, with mitigation efforts ongoing. He and CEO Franco Stevanato noted that the Fishers, IN plant will increasingly offset tariff impacts as it ramps up. Dal Lago also reiterated the mid-to-high single-digit growth outlook for vials, supported by double-digit growth in order intake.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Stevanato Group SpA (STVN) leadership • Q4 2024

    Question

    Matthew Larew from William Blair followed up on the vial market, seeking specific growth expectations for 2025, and inquired about the company's strategy and ability to profitably scale its device manufacturing operations, including Nexa and Alba products.

    Answer

    CFO Marco Dal Lago indicated that the company is modeling mid-to-high single-digit growth for vials in 2025, with sequential improvements expected each quarter. He also outlined the strategy to provide integrated solutions, combining proprietary IP devices with contract manufacturing services to serve as a comprehensive partner for biologic customers.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Stevanato Group SpA (STVN) leadership • Q3 2024

    Question

    Matthew Larew from William Blair asked for an update on vial destocking visibility across different customer groups and inquired about how much of the Engineering segment's recovery is within the company's control.

    Answer

    CEO Franco Stevanato described the vial market as "normalizing" but still a "mixed bag," with gradual order improvements seen in smaller markets and positive forecasts from larger customers for 2025. Regarding Engineering, he and CFO Marco Dal Lago detailed an optimization plan to restore profitability, with Executive Lisa Miles confirming the execution is now "largely within our control."

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Bio-Techne Corp (TECH) leadership

    Matthew Larew's questions to Bio-Techne Corp (TECH) leadership • Q3 2025

    Question

    Matthew Larew of William Blair questioned the fiscal 2026 growth outlook given new headwinds and asked about the drivers of the strong Q3 operating margin and where future leverage opportunities exist.

    Answer

    CFO Jim Hippel described the current market disruption as an abrupt but likely temporary 'jolt,' stating that once uncertainty resolves, the company can resume its prior growth trajectory. He attributed the strong Q3 margin to solid revenue performance combined with diligent discretionary cost control. CEO Kim Kelderman added that efficiency gains from process improvements, acquisition integration, and disciplined R&D investment are key drivers of profitability.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Bio-Techne Corp (TECH) leadership • Q1 2025

    Question

    Matthew Larew from William Blair & Company questioned whether the biotech and biopharma recovery was driven by the return of paused projects or new work. He also asked for an assessment of the competitive standing of the Wilson Wolf G-Rex offering.

    Answer

    CEO Kim Kelderman stated that the momentum in cell and gene therapy is broad-based, coming from all three areas: existing customers progressing to later clinical phases with larger orders, increased order frequency from smaller accounts, and the addition of a good portion of new customers to the funnel. Regarding the Wilson Wolf partnership, Kelderman expressed high confidence in the G-Rex bioreactor's competitive advantages in scalability, cost, and performance, and highlighted the strategic importance of grant programs to seed the market and drive adoption of the combined Bio-Techne and G-Rex solution.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Bio-Techne Corp (TECH) leadership • Q2 2024

    Question

    Matthew Larew asked for a breakdown of biopharma growth between large pharma and smaller biotech customers. He also inquired about the competitive landscape for the Lunaphore spatial biology platform and its path to profitability.

    Answer

    CEO Kim Kelderman and CFO Jim Hippel noted that while smaller biotech recovery is on track, the earlier-than-expected recovery in large pharma was a positive surprise. Regarding Lunaphore, Kelderman stated that the multiomic COMET platform is now rolling out and is expected to have high consumable pull-through, with profitability improving as instrument placements and reagent sales scale.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Twist Bioscience Corp (TWST) leadership

    Matthew Larew's questions to Twist Bioscience Corp (TWST) leadership • Q2 2025

    Question

    Matthew Larew asked if the company's emphasis on 'continued share taking' implies an observation of softer market conditions or customer spending, and requested commentary on broad customer behavior.

    Answer

    CEO Emily Leproust explained that market dynamics are segmented: academia faces funding pressure where Twist's value proposition excels, while NGS diagnostics and liquid biopsy are performing very well. In biopharma, Twist's brand of quality, speed, and cost resonates with both well-funded and budget-conscious customers. She stressed that Twist's strength lies in adapting its approach to these varied market conditions.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Twist Bioscience Corp (TWST) leadership • Q1 2025

    Question

    Matthew Larew of William Blair requested performance metrics for the Express portfolio one year after launch, such as customer conversion and wallet share, and asked about win rates against competitors' responsive offerings.

    Answer

    CEO Emily Leproust highlighted high customer satisfaction and the achievement of key goals: ramping revenue, expanding gross margin (with 81% of incremental revenue dropping to the margin line in Q1), and acquiring new customers. She dismissed competitive responses as having limited capacity and different pricing, stating Twist does not see them as a significant factor in the market.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Twist Bioscience Corp (TWST) leadership • Q4 2024

    Question

    Matthew Larew asked why gross margin exceeded expectations, given the revenue upside was in SynBio, and followed up with questions about initiatives for the academic market and a confirmation on the change in reporting for orders.

    Answer

    CFO Adam Laponis attributed the gross margin beat to the company's model where 75-80% of incremental revenue drops to gross profit, strong performance from Express Genes, and various operational initiatives. He also confirmed that going forward, Twist will only provide order disclosures for the biopharma segment. CEO Dr. Emily Leproust added that the company is focused on streamlining the academic ordering process through e-commerce integrations ('punch-outs') with university systems, which is showing positive early results.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Aptargroup Inc (ATR) leadership

    Matthew Larew's questions to Aptargroup Inc (ATR) leadership • Q1 2025

    Question

    Matthew Larew of William Blair asked about the growth cadence in Pharma, given recent choppiness from cough/cold destocking and emergency medicine strength, and requested an update on emergency medicine's sales contribution. He also sought confirmation that the Q2 guidance fully incorporates the net effect of tariffs.

    Answer

    President and CEO Stephan Tanda stated that emergency medicines constitute about 5% of total company revenue and acknowledged the business is inherently 'lumpy.' He reiterated confidence in the long-term 7%-11% Pharma growth target. Executive Vice President and CFO Vanessa Kanu confirmed that the Q2 guidance includes the limited net effect of tariffs, as the company is passing on costs and identifying new opportunities.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Aptargroup Inc (ATR) leadership • Q4 2024

    Question

    Matthew Larew asked for clarification on Pharma royalties, questioning if there were any one-time payments and how to model their future contribution. He also followed up on Injectables, asking if the business would be down in Q1 given the tough comparison and slow ramp.

    Answer

    President and CFO Stephan Tanda explained that royalties are tied to finished product sales from long-term development partnerships, not one-time milestones, and while lumpy, they are a growing revenue stream. On Injectables, he did not provide specific Q1 guidance but highlighted that underlying unit volume grew throughout the year, though reported results are also affected by lumpy service revenue.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Aptargroup Inc (ATR) leadership • Q3 2024

    Question

    Matthew Larew of William Blair inquired about the Injectables business, asking if destocking was still not an issue and when a more regular growth cadence could be expected given new capacity. He also asked about the current profitability of the Injectables segment and its potential for improvement.

    Answer

    CEO Stephan Tanda acknowledged some destocking in the antithrombotic area but stated the overall pipeline for Injectables is building, expressing bullishness for next year with growth drivers like GLP-1s and biologics. He expects the business to return to high single-digit to low double-digit growth. Tanda explained that Injectables' profitability is generally in line with the company average when at good capacity utilization, below the more profitable proprietary drug delivery systems. As the business grows and scales, its profitability is expected to improve.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Option Care Health Inc (OPCH) leadership

    Matthew Larew's questions to Option Care Health Inc (OPCH) leadership • Q1 2025

    Question

    Matthew Larew asked about the sustainability of the strong acute therapy growth, comparing the current market opportunity to a similar period of competitive disruption a few years ago. He also sought clarity on the timing of reference price updates in contracts and the company's exposure to other major branded drugs facing biosimilar competition after Stelara.

    Answer

    CFO Michael Shapiro clarified that while they don't expect mid-teens growth to be sustainable for the acute portfolio, they had a 'better playbook' this time to capitalize on market shifts and expect to build from this higher revenue base. He also explained that procurement and reimbursement prices generally align within a year. CEO John Rademacher stated that no other single product represents more than 5% of revenue and the company does not see significant risk from other biosimilars on the horizon.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Option Care Health Inc (OPCH) leadership • Q4 2024

    Question

    Matthew Larew of William Blair asked about the outlook for the acute care business, considering the resolution of supply chain issues and shifts in the competitive landscape. He also inquired about the company's long-term growth algorithm, including the new adjusted EPS metric, and whether any other one-off events like the STELARA headwind could impact future performance.

    Answer

    CEO John Rademacher confirmed that IV solution supply chain issues have been resolved and are no longer a constraint on onboarding new patients. He stated that Option Care Health is well-positioned to capture market share due to its national platform and local responsiveness. CFO Michael Shapiro reaffirmed the long-term targets of high single-digit revenue and low double-digit EBITDA growth, adding that adjusted EPS should grow faster than EBITDA due to capital deployment. He expressed confidence in managing portfolio dynamics, citing a strong pipeline and the advanced practitioner model as offsetting factors.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Option Care Health Inc (OPCH) leadership • Q3 2024

    Question

    Matthew Larew sought to confirm that the STELARA pricing impact is a 2025 issue, not affecting Q4 2024, and asked if growth would continue despite headwinds. He also inquired about the patient payment delays from the Change Healthcare disruption, asking if it was a one-time issue.

    Answer

    CFO Michael Shapiro confirmed the STELARA impact is expected in early 2025 with no impact in 2024. He highlighted strong top-line momentum and sequential gross profit dollar growth. Regarding patient payments, Shapiro noted that while they were still recovering from the Change Healthcare disruption in Q3, strong cash flow affirms they have effectively managed the situation and the ability to convert revenue to cash remains high.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to West Pharmaceutical Services Inc (WST) leadership

    Matthew Larew's questions to West Pharmaceutical Services Inc (WST) leadership • Q1 2025

    Question

    Matthew Larew questioned the confidence in the timeline for the new automated SmartDose line. He also asked a broader question on the long-term growth impact of GLP-1s, considering the rise of oral alternatives.

    Answer

    CEO Eric Green affirmed that the automated line project is on schedule for validation by year-end. Regarding GLP-1s, he stated that West's forecasts have already factored in the potential impact of orals, and the company remains confident that injectables will be the primary delivery method. He also highlighted the fungibility of assets, allowing them to pivot to meet GLP-1 demand.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to West Pharmaceutical Services Inc (WST) leadership • Q4 2024

    Question

    Matthew Larew of William Blair & Company raised a strategic question about the long-term viability of the drug delivery device business, specifically SmartDose, as a core competency given its financial challenges. He also asked for details on the new multiyear GLP-1 contract.

    Answer

    CEO Eric Green acknowledged the need to improve SmartDose economics and confirmed the company is evaluating all long-term options to maximize shareholder value. Regarding the GLP-1 contract, he explained it secures West's existing position as the sole elastomer component provider for a key customer over a lengthy, multiyear period, calling it a natural progression of their relationship.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to West Pharmaceutical Services Inc (WST) leadership • Q3 2024

    Question

    Matthew Larew questioned the potential for gross margin expansion in the Contract Manufacturing segment, given its strong sequential performance. He also requested a 'state of the union' on the size and growth outlook for West's GLP-1 related business.

    Answer

    CFO Bernard Birkett projected that Contract Manufacturing margins would remain relatively consistent in the high-teens for the next 12-24 months, with a significant step-up being a longer-term event as the higher-margin drug handling business scales. CEO Eric Green did not quantify the GLP-1 opportunity but confirmed West's participation through both proprietary components and selective contract manufacturing, noting that existing capital investments largely support the near-term growth.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Repligen Corp (RGEN) leadership

    Matthew Larew's questions to Repligen Corp (RGEN) leadership • Q4 2024

    Question

    Matthew Larew from William Blair asked about the visibility into the Proteins franchise achieving its 10-15% growth target for 2025, given its significant decline in 2024, and inquired about traction with new product launches.

    Answer

    President and CEO Olivier Loeillot explained that 2024 was a 'reset year' for Proteins, with demand from top OEM partners now near zero, effectively removing that headwind. He expressed confidence in returning to double-digit growth, driven by custom ligand wins, the Avitide and Tantti businesses, and new resin launches like the double-stranded RNA resin. Loeillot stressed that Repligen now has much more direct control over the franchise's future.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to Repligen Corp (RGEN) leadership • Q3 2024

    Question

    Matthew Larew inquired about the success with large pharma accounts through the enterprise sales strategy and sought current thoughts on the China business and the impact of the BioSecure Act.

    Answer

    President and CEO Olivier Loeillot credited the key account management team for gaining traction and platform wins at large pharma by presenting the entire portfolio to higher-level decision-makers. Regarding China, he noted it's a small part of revenue but hopes for a rebound. He also confirmed that some smaller CDMOs are seeing increased inquiries due to the BioSecure Act.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to 10X Genomics Inc (TXG) leadership

    Matthew Larew's questions to 10X Genomics Inc (TXG) leadership • Q4 2024

    Question

    Matthew Larew asked if it was reasonable to expect single-cell revenue growth by Q4 2025 given the product transition, and how customer behavior in Europe, which has lower indirect cost rates, might serve as a comparison for the current US situation.

    Answer

    CEO Serge Saxonov used the European business as a point of comparison, noting it has performed well and indicates that research can remain robust with lower indirect rates. However, he cautioned that the sudden and significant nature of the potential change in the US is creating a high degree of uncertainty for customers, making a direct comparison difficult in the short term.

    Ask Fintool Equity Research AI

    Matthew Larew's questions to 10X Genomics Inc (TXG) leadership • Q3 2024

    Question

    Matthew Larew asked for more quantitative detail on the single-cell volume growth mentioned in the prepared remarks. He requested the reaction volume growth rate for the quarter and year-to-date, and how that growth compares to the overall market's growth rate.

    Answer

    CEO Serge Saxonov declined to provide a specific quarterly reaction volume metric, stating that the company shares that data on an annual basis. However, he offered an alternative indicator: the number of cells analyzed. He noted that due to new high-throughput products, the growth in total cells processed has been "really robust and significant," indicating healthy underlying market growth and adoption of larger-scale experiments.

    Ask Fintool Equity Research AI